This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
by Zacks Equity Research
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
by Zacks Equity Research
Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective targeting of MTAP-deleted tumors.
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
by Zacks Equity Research
Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
by Zacks Equity Research
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
by Zacks Equity Research
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
by Zacks Equity Research
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
by Zacks Equity Research
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
by Zacks Equity Research
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
by Zacks Equity Research
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
by Zacks Equity Research
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
by Zacks Equity Research
Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
by Zacks Equity Research
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
by Zacks Equity Research
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Novartis Reports Updated Positive Data From Phase III SMA Program
by Zacks Equity Research
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
by Zacks Equity Research
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
by Zacks Equity Research
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan
by Zacks Equity Research
Amarin incurs a wider-than-expected loss in Q4. Revenues beat estimates. It plans to initiate a ratio change on its American Depositary Shares. Stock falls.
Wall Street Analysts See an 83.1% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 83.1% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25% and 0.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 93.2%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 93.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies (DVAX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).